Normalization of Tumour Blood Vessels Improves the Delivery of Nanomedicines in a Size-dependent Manner

Overview

Journal Nat Nanotechnol

Specialty Biotechnology

Date 2012 Apr 10

PMID 22484912

Citations 402

Authors

Vikash P Chauhan

Triantafyllos Stylianopoulos

John D Martin

Zoran Popovic

Ou Chen

Walid S Kamoun

Moungi G Bawendi

Dai Fukumura

Rakesh K Jain

Affiliations

Soon will be listed here.

Abstract

The blood vessels of cancerous tumours are leaky and poorly organized. This can increase the interstitial fluid pressure inside tumours and reduce blood supply to them, which impairs drug delivery. Anti-angiogenic therapies--which 'normalize' the abnormal blood vessels in tumours by making them less leaky--have been shown to improve the delivery and effectiveness of chemotherapeutics with low molecular weights, but it remains unclear whether normalizing tumour vessels can improve the delivery of nanomedicines. Here, we show that repairing the abnormal vessels in mammary tumours, by blocking vascular endothelial growth factor receptor-2, improves the delivery of smaller nanoparticles (diameter, 12 nm) while hindering the delivery of larger nanoparticles (diameter, 125 nm). Using a mathematical model, we show that reducing the sizes of pores in the walls of vessels through normalization decreases the interstitial fluid pressure in tumours, thus allowing small nanoparticles to enter them more rapidly. However, increased steric and hydrodynamic hindrances, also associated with smaller pores, make it more difficult for large nanoparticles to enter tumours. Our results further suggest that smaller (∼12 nm) nanomedicines are ideal for cancer therapy due to their superior tumour penetration.

Citing Articles

Computational Evaluation of Improved HIPEC Drug Delivery Kinetics via Bevacizumab-Induced Vascular Normalization.

Namakshenas P, Crezee J, Tuynman J, Tanis P, Oei A, Kok H Pharmaceutics. 2025; 17(2).

PMID: 40006522 PMC: 11859678. DOI: 10.3390/pharmaceutics17020155.

Using mathematical modelling and AI to improve delivery and efficacy of therapies in cancer.

Harkos C, Hadjigeorgiou A, Voutouri C, Kumar A, Stylianopoulos T, Jain R Nat Rev Cancer. 2025; .

PMID: 39972158 DOI: 10.1038/s41568-025-00796-w.

Optical and MRI-Guided Theranostic Application of Ultrasmall Superparamagnetic Iron Oxide Nanodrug Conjugate for PSMA-Positive Prostate Cancer Therapy.

Surasinghe S, Liatsou I, Novakova Z, Barinka C, Artemov D, Hapuarachchige S ACS Appl Mater Interfaces. 2025; 17(8):11611-11623.

PMID: 39933703 PMC: 11873945. DOI: 10.1021/acsami.4c16009.

Mathematical modelling of hollow microneedle-mediated transdermal drug delivery.

Benbrook N, Zhan W Drug Deliv Transl Res. 2025; .

PMID: 39913061 DOI: 10.1007/s13346-025-01801-3.

Hybrid model of tumor growth, angiogenesis and immune response yields strategies to improve antiangiogenic therapy.

Hadjigeorgiou A, Stylianopoulos T Unknown. 2025; 1(1):4.

PMID: 39759959 PMC: 11698377. DOI: 10.1038/s44341-024-00002-2.

References

Baish J, Stylianopoulos T, Lanning R, Kamoun W, Fukumura D, Munn L . Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc Natl Acad Sci U S A. 2011; 108(5):1799-803. PMC: 3033252. DOI: 10.1073/pnas.1018154108. View

Hobbs S, Monsky W, Yuan F, ROBERTS W, Griffith L, Torchilin V . Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A. 1998; 95(8):4607-12. PMC: 22537. DOI: 10.1073/pnas.95.8.4607. View

Sarin H . Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res. 2010; 2:14. PMC: 2928191. DOI: 10.1186/2040-2384-2-14. View

Tong R, Boucher Y, Kozin S, Winkler F, Hicklin D, Jain R . Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004; 64(11):3731-6. DOI: 10.1158/0008-5472.CAN-04-0074. View

Chauhan V, Stylianopoulos T, Boucher Y, Jain R . Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng. 2012; 2:281-98. DOI: 10.1146/annurev-chembioeng-061010-114300. View

Willett C, Boucher Y, Tomaso E, Duda D, Munn L, Tong R . Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10(2):145-7. PMC: 2693485. DOI: 10.1038/nm988. View

Jain R, Baxter L . Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988; 48(24 Pt 1):7022-32. View

Jain R, Stylianopoulos T . Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010; 7(11):653-64. PMC: 3065247. DOI: 10.1038/nrclinonc.2010.139. View

Ruoslahti E, Bhatia S, Sailor M . Targeting of drugs and nanoparticles to tumors. J Cell Biol. 2010; 188(6):759-68. PMC: 2845077. DOI: 10.1083/jcb.200910104. View

10.

Popovic Z, Liu W, Chauhan V, Lee J, Wong C, Greytak A . A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl. 2010; 49(46):8649-52. PMC: 3035057. DOI: 10.1002/anie.201003142. View

11.

Chauhan V, Popovic Z, Chen O, Cui J, Fukumura D, Bawendi M . Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed Engl. 2011; 50(48):11417-20. PMC: 3260125. DOI: 10.1002/anie.201104449. View

12.

Nakahara T, Norberg S, Shalinsky D, Hu-Lowe D, McDonald D . Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res. 2006; 66(3):1434-45. DOI: 10.1158/0008-5472.CAN-05-0923. View

13.

Sorensen A, Emblem K, Polaskova P, Jennings D, Kim H, Ancukiewicz M . Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2011; 72(2):402-7. PMC: 3261301. DOI: 10.1158/0008-5472.CAN-11-2464. View

14.

Pozrikidis C, Farrow D . A model of fluid flow in solid tumors. Ann Biomed Eng. 2003; 31(2):181-94. DOI: 10.1114/1.1540103. View

15.

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

16.

Baish J, Netti P, Jain R . Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. Microvasc Res. 1997; 53(2):128-41. DOI: 10.1006/mvre.1996.2005. View

17.

Hashizume H, Baluk P, Morikawa S, McLean J, Thurston G, Roberge S . Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000; 156(4):1363-80. PMC: 1876882. DOI: 10.1016/S0002-9440(10)65006-7. View

18.

Nagy J, Dvorak A, Dvorak H . VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol. 2007; 2:251-75. DOI: 10.1146/annurev.pathol.2.010506.134925. View

19.

Winkler F, Kozin S, Tong R, Chae S, Booth M, Garkavtsev I . Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004; 6(6):553-63. DOI: 10.1016/j.ccr.2004.10.011. View

20.

Gazit Y, Baish J, Safabakhsh N, Leunig M, Baxter L, Jain R . Fractal characteristics of tumor vascular architecture during tumor growth and regression. Microcirculation. 1998; 4(4):395-402. DOI: 10.3109/10739689709146803. View